D

David Isenberg

Regenerative Medicine Institute

ORCID: 0000-0001-9514-2455

1.8k papers and 88.3k citations.

PubIndex Score98Top 2%How it's scored

🌟#3 Current Senior Leader in Systemic Lupus Erythematosus Research

1.8kPublications

88.3kTotal Citations

#3in Systemic Lupus Erythematosus Research

First publication: 1971First senior author: 1984

Top publicationsby citations

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

Ronald van Vollenhoven, Matthias Schneider, Carlos Vasconcelos et al.|Annals of the Rheumatic Diseases|2014

Cited by 726

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

Hannah Cohen, David Isenberg, Beverley J. Hunt et al.|The Lancet Haematology|2016

Cited by 404

International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease

David Isenberg, Frederick W. Miller, Elizabeth Allen et al.|Lara D. Veeken|2003

Cited by 367

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

Ronald van Vollenhoven, Murray B. Urowitz, Alexandre E. Voskuyl et al.|Annals of the Rheumatic Diseases|2016

Cited by 355

2021 DORIS definition of remission in SLE: final recommendations from an international task force

Ronald van Vollenhoven, Y K Onno Teng, George Βertsias et al.|Lupus Science & Medicine|2021

Cited by 340

Indexing the rest of 1,816 publications…